Today: 9 June 2026
Sembcorp share price ends week higher as Alinta vote and Feb 25 results line up
18 January 2026
1 min read

Sembcorp share price ends week higher as Alinta vote and Feb 25 results line up

Singapore, Jan 18, 2026, 15:29 SGT — Market closed

  • On Friday, Sembcorp shares ended the day 2.3% higher, closing at S$6.12
  • Shareholders will cast their votes on the Alinta Energy acquisition proposal on Jan 30; proxy submissions are due by Jan 27
  • FY2025 results will be released Feb 25 before the market opens, followed by a briefing webcast later that morning

Sembcorp Industries Ltd (SGX:U96) shares climbed 2.3% to close at S$6.12 on Friday, with roughly 6.1 million shares changing hands. The pause in trading on Sunday means attention now turns to a key deal vote and when the company will release its full-year results.

This matters now because the proposed acquisition in Australia would reshape Sembcorp’s portfolio, add debt, and force the company to reset its climate targets. The stock has been trading on “deal versus dilution” math, and these next dates are where that debate gets tested in public.

Sembcorp is set to report its FY2025 financial results before markets open on Feb 25. A live webcast of the results briefing will follow at 11 a.m. Singapore time.

The shareholder vote takes priority. According to an SGX filing, Sembcorp plans an extraordinary general meeting on Jan 30 at 10 a.m., held at the Fairmont Hotel in Singapore. Proxy submissions must be in by 10 a.m. on Jan 27.

In a circular to shareholders, Sembcorp set the agreed enterprise value — which includes debt — at A$6.5 billion (around S$5.6 billion) and confirmed it will pay cash on completion. The company plans to arrange long-term debt financing but has lined up a fully committed A$6.5 billion bridge facility, a short-term bank loan, to cover the purchase if longer-term debt isn’t secured in time. The circular highlighted Alinta’s 10.4-gigawatt development pipeline along with pro forma boosts to earnings per share and return on equity. On the flip side, Sembcorp expects pro forma emissions intensity to climb to about 0.36 tonnes of CO2 equivalent per megawatt hour and absolute emissions to 18.1 million tonnes of CO2e by 2025. It also acknowledged it would miss its 2028 and 2030 targets, while aiming for a 0.26 tCO2e/MWh intensity target by 2035 and net zero (Scope 1 and 2) by 2050.

Citi Research analyst Luis Hilado described the deal as both “half-full” and “half-empty,” noting it might boost earnings but hinder Sembcorp’s decarbonisation efforts. The Business Times

The journey from vote to completion isn’t always smooth. Rising funding costs, stricter Australian regulations, or delays in securing financing could all reshape expected returns and fuel stock volatility.

Traders have a clear short-term focus: proxy flows into Jan 27, followed by the Jan 30 vote. After those dates, the spotlight moves sharply to Feb 25 — not just the numbers, but crucially any updates on leverage, funding mix, and management’s strategy for balancing growth against the updated emissions profile.

Stock Market Today

  • $150M Cancer Proteomics Deal Spurs New NYSE Listing
    June 9, 2026, 9:34 AM EDT. A $150 million deal in functional proteomics, the study of protein functions and interactions critical for drug development, has led to the spin-out of a new company set to list on the New York Stock Exchange (NYSE). The company focuses on advanced cancer treatments including antibody-drug conjugates-targeted therapies combining antibodies with cell-killing agents to attack tumors precisely. Immunotherapies and targeted therapies featured in the pipeline aim to harness and guide the immune system to combat cancer effectively. Filing of the registration statement with regulators marks a key step toward public investment, enabling transparency. This development highlights the growing financial and clinical importance of proteomics in oncology and the biotech sector.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
CBA share price: Commonwealth Bank stock in focus before the RBA call and February earnings
Previous Story

CBA share price: Commonwealth Bank stock in focus before the RBA call and February earnings

Singapore Airlines stock price: Air India pact in focus after C6L closes at S$6.35
Next Story

Singapore Airlines stock price: Air India pact in focus after C6L closes at S$6.35

Go toTop